Trial Profile

Therapeutic Safety and Efficacy of REP 2139 (REP 9AC') in HBV Infected Patients

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 11 Aug 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs REP 2139 (Primary) ; Peginterferon alfa-2a; Thymalfasin
Indications Hepatitis B
Focus Adverse reactions; Proof of concept
Sponsors REPLICor

Most Recent Events

14 Apr 2018 Results assessing mathematical model that predicts HBV DNA, HBsAg and transamin- ase kinetic parameters against HBV during REP 2139 monotherapy in the REP 102 protocol (NCT02646189) presented at The International Liver Congress 2018
07 Jun 2016 Results published in the journal PLOS ONE, according to a REPLICor media release.
07 Jun 2016 Results published in a REPLICor media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com